Bendroflumethiazide - Generic Drug Details
What are the generic sources for bendroflumethiazide and what is the scope of patent protection?
Bendroflumethiazide
is the generic ingredient in five branded drugs marketed by Apothecon, King Pharms Llc, Impax Labs, and Natco Pharma, and is included in four NDAs. Additional information is available in the individual branded drug profile pages.Summary for bendroflumethiazide
| US Patents: | 0 |
| Tradenames: | 5 |
| Applicants: | 4 |
| NDAs: | 4 |
| Drug Master File Entries: | 4 |
| Raw Ingredient (Bulk) Api Vendors: | 76 |
| Clinical Trials: | 5 |
| DailyMed Link: | bendroflumethiazide at DailyMed |
Recent Clinical Trials for bendroflumethiazide
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | PHASE1 |
| Yale University | PHASE1 |
| Yale University | Phase 1 |
Medical Subject Heading (MeSH) Categories for bendroflumethiazide
Anatomical Therapeutic Chemical (ATC) Classes for bendroflumethiazide
US Patents and Regulatory Information for bendroflumethiazide
Bendroflumethiazide Market Dynamics, Patent Status, FDA Regulation, and Financial Trajectory
Bendroflumethiazide is a mature thiazide diuretic with minimal branded commercial value, no meaningful remaining patent barrier, and limited growth potential. Its market is driven by low-cost generic supply, legacy prescribing, and use in combination products rather than by innovation or premium pricing. Public company filings generally do not disclose bendroflumethiazide revenue separately, preventing a reliable global sales estimate.
What is bendroflumethiazide used for?
Bendroflumethiazide is an oral thiazide diuretic used primarily for hypertension and edema associated with conditions such as congestive heart failure, hepatic disease, and renal disorders. It increases urinary sodium and water excretion by inhibiting sodium reabsorption in the distal convoluted tubule.
The drug is typically administered once daily. Common clinical risks include hypokalemia, hyponatremia, dehydration, hyperuricemia, glucose intolerance, and renal-function changes. Product labeling also identifies interactions with lithium, nonsteroidal anti-inflammatory drugs, corticosteroids, and other medicines affecting electrolyte balance.[1]
Bendroflumethiazide has largely been displaced in many markets by hydrochlorothiazide, indapamide, and chlorthalidone. It remains relevant in the United Kingdom and selected international markets where physicians continue to use older thiazide regimens or fixed-dose combinations.
What therapeutic category does bendroflumethiazide belong to?
| Attribute | Bendroflumethiazide |
|---|---|
| Therapeutic class | Thiazide diuretic |
| Primary uses | Hypertension; edema |
| Typical dosage form | Immediate-release oral tablet |
| Common strength | 2.5 mg |
| Administration | Oral, generally once daily |
| Prescription status | Prescription medicine in major regulated markets |
| Biosimilar relevance | None |
| Main substitutes | Hydrochlorothiazide, indapamide, chlorthalidone, loop diuretics |
How large is the bendroflumethiazide market?
The standalone bendroflumethiazide market is small and fragmented. No major originator company reports the product as a separate revenue line, and publicly available market databases do not provide a consistent, auditable global sales figure. Revenue is generally embedded within broader generic cardiovascular or diuretic portfolios.
The commercial market has four defining characteristics:
- Low average selling prices.
- Mature demand with limited volume growth.
- Competition among a small number of suppliers in some countries.
- Periodic supply constraints caused by low manufacturing incentives.
The drug’s demand base is sustained by established clinical practice rather than new diagnosis growth. Hypertension prevalence supports the broader diuretic market, but most incremental demand flows to newer or more commonly stocked agents. Prescribers often select hydrochlorothiazide, indapamide, or chlorthalidone because those products have broader availability, more extensive guideline recognition, or stronger formulary support.
What drives bendroflumethiazide demand?
Demand is concentrated in:
- Legacy prescriptions that are not routinely switched.
- Primary-care treatment of hypertension.
- Combination products containing a thiazide diuretic.
- National health systems with established bendroflumethiazide prescribing patterns.
- Patients stabilized on a specific low-dose regimen.
Demand is constrained by generic substitution, clinical preference for alternative thiazides, declining use of older fixed-dose combinations, and limited promotional activity.
What is the financial trajectory for bendroflumethiazide?
Bendroflumethiazide has a declining or flat value trajectory, with any remaining revenue dependent on retention of low-cost prescription volume. The product has little capacity to generate price expansion because its active ingredient and dosage form are well established and competing thiazide products are available.
| Financial factor | Expected impact |
|---|---|
| Unit volume | Stable to declining |
| Net price | Flat or declining |
| Gross margin | Variable; vulnerable to input and compliance costs |
| Brand investment | Minimal |
| Generic competition | High where multiple suppliers remain |
| Supply concentration | Potentially high in smaller markets |
| Revenue visibility | Low because sales are not separately reported |
| Growth prospects | Limited without a combination-product or geographic strategy |
Manufacturers may retain the product because production is technically straightforward, regulatory files are established, and the medicine can complement a broader generic portfolio. The economic case weakens when active pharmaceutical ingredient costs, quality-control requirements, serialization, pharmacovigilance, and distribution expenses rise.
In a low-volume market, a supplier can face an unfavorable cost structure even when competition is limited. That dynamic can produce shortages or product withdrawals without creating durable pricing power. Health-system procurement rules also limit the ability of a supplier to recover higher manufacturing costs.
What patents protect bendroflumethiazide?
No commercially important composition-of-matter patent is expected to remain in force for bendroflumethiazide. The active ingredient was developed and commercialized many decades ago, placing any original molecule, formulation, and basic-use patent protection well beyond ordinary patent terms.
| Patent category | Current commercial relevance |
|---|---|
| Original compound patent | Expired |
| Original formulation patent | Expired |
| Basic hypertension use patent | Expired |
| Fixed-dose combination patents | Generally expired for legacy combinations |
| Manufacturing-process patents | Unlikely to block routine generic production |
| New formulation patents | Possible in theory, but no major current estate is evident |
| Regulatory exclusivity | No meaningful modern exclusivity expected |
A generic manufacturer could still obtain a patent on a genuinely new formulation, manufacturing process, or combination. Such a patent would not restore exclusivity for the underlying bendroflumethiazide molecule and would have to satisfy novelty, inventive-step, and other national requirements.
When did bendroflumethiazide lose exclusivity?
Bendroflumethiazide lost practical exclusivity decades ago. The exact expiration date of the original patent family is not the primary commercial issue because the product has been generic for a prolonged period and is not supported by an active originator franchise.
The product does not have the commercial profile of a recently approved small molecule with patent-term adjustment, pediatric exclusivity, or a long Orange Book tail. Any modern market protection would depend on a new product presentation or combination rather than the active ingredient itself.
What is the FDA and Orange Book status of bendroflumethiazide?
Bendroflumethiazide does not have a meaningful current U.S. branded market comparable with widely used hydrochlorothiazide or chlorthalidone products. The FDA Orange Book is principally relevant to approved prescription drug applications and listed patents. It does not create exclusivity for an old active ingredient merely because the ingredient remains known or used outside the United States.[2]
No active U.S. patent barrier is generally associated with bendroflumethiazide monotherapy. Historical U.S. products and applications, where present in FDA records, do not provide a current commercial moat for the molecule.
Does bendroflumethiazide have FDA regulatory exclusivity?
No material current FDA exclusivity is expected. The product is not a biologic, so biosimilar exclusivity rules do not apply. It also does not benefit from the new chemical entity exclusivity period available to qualifying innovative drugs.
A U.S. company seeking to commercialize the product would require an appropriate FDA approval pathway, generally involving an approved drug application or a suitable abbreviated pathway where reference-product and regulatory conditions permit. The practical obstacle would be commercial economics rather than patent exclusivity.
Are there Paragraph IV challenges for bendroflumethiazide?
Paragraph IV litigation risk appears low because there is no prominent current branded bendroflumethiazide product with a valuable, unexpired Orange Book patent estate. Paragraph IV certifications typically matter when a generic applicant challenges patents listed for an active reference product. That structure is largely absent for this mature molecule.
A future Paragraph IV dispute could arise only if a company obtained approval for a protected new formulation or combination and listed qualifying patents. Such a case would concern the protected presentation, not the historic bendroflumethiazide compound.
Which companies manufacture or market bendroflumethiazide?
Bendroflumethiazide is associated primarily with generic and legacy-market suppliers rather than an active global innovator. In the United Kingdom, products have historically been supplied under generic names through companies including Actavis, Teva, and other national-license holders, although product availability and marketing authorization status can change.
Supplier mapping requires country-level review because a company may hold a marketing authorization without actively distributing the product. National regulatory databases, medicine shortage notices, and pharmacy purchasing records are more informative than global company reports for this product.
What formulations contain bendroflumethiazide?
The commercially relevant formulation is the immediate-release tablet. Some historical products used bendroflumethiazide in combination with potassium-sparing diuretics or other cardiovascular agents.
Potential formulation categories include:
- Bendroflumethiazide monotherapy tablets.
- Bendroflumethiazide with potassium-sparing agents.
- Historical antihypertensive combinations.
- Extemporaneous or pharmacy-directed dosage adjustments.
Legacy combination products may have separate authorization histories and different supply risks. Their patent estates are generally old, but regulatory maintenance can be more difficult because each active ingredient, strength, and presentation must remain commercially viable.
How does bendroflumethiazide compare with hydrochlorothiazide and indapamide?
Hydrochlorothiazide has broader international recognition and a larger generic supplier base. Indapamide has a strong position in several hypertension markets and is often selected when clinicians prefer a thiazide-like agent with established cardiovascular evidence. Chlorthalidone is valued for longer duration of action but can have a higher electrolyte and metabolic monitoring burden.
| Product | Market position | Competitive advantage |
|---|---|---|
| Bendroflumethiazide | Legacy, geographically concentrated | Familiarity and low cost |
| Hydrochlorothiazide | Broad global generic availability | Extensive supply and combination use |
| Indapamide | Strong hypertension position in several markets | Thiazide-like profile and guideline use |
| Chlorthalidone | Important specialist and guideline option | Long duration of action |
| Furosemide | Dominant loop diuretic | Stronger use in significant fluid overload |
Bendroflumethiazide competes primarily on continuity and price. It does not have a clear clinical or commercial differentiator capable of supporting premium pricing.
What generic entry risks exist for bendroflumethiazide?
Generic entry risk is structurally high because the molecule is old, the dosage form is simple, and the patent barrier is not commercially significant. The more relevant risk for existing suppliers is reverse pressure from competing generics and product discontinuation.
The principal risks are:
- Additional suppliers entering a small market.
- Tender-driven price erosion.
- Substitution by hydrochlorothiazide or indapamide.
- Loss of a manufacturing site or active ingredient source.
- Regulatory withdrawal caused by low sales.
- Shortages when only one or two suppliers remain.
For buyers and health systems, a low price does not eliminate supply risk. A mature low-volume product can become less reliable when manufacturers reduce inventory or exit the market.
What manufacturing and intellectual-property barriers remain?
Manufacturing bendroflumethiazide tablets does not require a novel delivery system or complex biologic process. The main technical requirements are control of content uniformity, dissolution, impurity profile, stability, packaging, and validated manufacturing processes.
The most relevant barriers are operational:
- Reliable active pharmaceutical ingredient sourcing.
- Compliance with current good manufacturing practices.
- Stability data for the marketed strength and packaging.
- Bioequivalence or other applicable regulatory evidence.
- Qualified contract manufacturing capacity.
- Pharmacovigilance and post-approval maintenance.
Process patents are unlikely to prevent routine production, but a manufacturer still must control its own process and avoid infringing any narrowly drafted, later-filed patent covering a specific preparation method.
Does bendroflumethiazide have biosimilar risk?
Biosimilar risk is irrelevant because bendroflumethiazide is a chemically synthesized small molecule. The competitive threat comes from conventional generic medicines, therapeutic substitution, and fixed-dose combination products.
The closest commercial risk is substitution by other thiazide or thiazide-like diuretics. Formularies may favor those agents because of availability, guideline positioning, or procurement economics.
What licensing deals and litigation affect bendroflumethiazide?
No major recent licensing transaction or high-value patent litigation is associated with bendroflumethiazide. The molecule’s commercial profile does not typically support large milestone payments, royalty structures, or acquisition premiums.
Any licensing activity is more likely to involve:
- Transfer of a national marketing authorization.
- Contract manufacturing.
- Distribution rights.
- Portfolio acquisitions involving multiple mature generic medicines.
- Supply agreements for a combination product.
The absence of major litigation is consistent with the lack of a valuable, unexpired patent estate. Regulatory disputes and supply-related commercial disagreements are more plausible than originator-generic patent litigation.
What geographic markets remain commercially relevant?
The United Kingdom is the clearest established market for bendroflumethiazide, although availability can vary by supplier and time. Other markets may retain the product under national approvals, but the drug does not have a broad, globally uniform commercial footprint.
| Geography | Commercial assessment |
|---|---|
| United Kingdom | Established legacy use; generic supply and availability are key issues |
| United States | Limited current commercial relevance |
| European Union | Country-specific availability; alternatives are more prominent |
| Emerging markets | Possible local use, but data visibility is limited |
| Hospital and tender markets | Price-sensitive and vulnerable to supplier withdrawal |
The geographic opportunity is therefore selective rather than global. A company could find value in a country with persistent demand and limited competition, but the opportunity would depend on reliable registration, reimbursement, and supply execution.
What is the outlook for bendroflumethiazide?
The base-case outlook is stable-to-declining volume, continued low pricing, and sporadic supply pressure. The product can remain commercially viable as part of a broad generic portfolio, but it is unlikely to become a material growth driver.
Upside would require one of three developments: renewed guideline adoption, a differentiated combination product, or a supply-constrained market that permits temporary price recovery. None changes the underlying fact that the active ingredient has no meaningful exclusivity.
Key Takeaways
- Bendroflumethiazide is a mature thiazide diuretic with limited standalone commercial value.
- Original compound and formulation exclusivity expired decades ago.
- No meaningful current Orange Book, FDA exclusivity, or Paragraph IV risk is associated with ordinary monotherapy.
- The United Kingdom is the principal identifiable legacy market.
- Revenue is not separately disclosed by major manufacturers.
- Generic competition, therapeutic substitution, and supply concentration define the market.
- The main investment case is portfolio efficiency, not product-led growth.
- Manufacturing and regulatory maintenance, rather than patent protection, are the main barriers to continued supply.
- Biosimilar risk does not apply.
- The financial trajectory is flat-to-declining, with possible short-term volatility during shortages.
FAQs about bendroflumethiazide market dynamics
Is bendroflumethiazide still prescribed in the United Kingdom?
Yes. It remains a legacy prescription medicine in the United Kingdom, although prescribing and supply depend on local clinical practice, reimbursement, and the availability of licensed products.
Can a company launch a generic bendroflumethiazide tablet?
A company may pursue approval where a viable regulatory pathway and reference product exist. The principal challenges are market size, manufacturing economics, and maintaining dependable supply rather than patent infringement.
Is bendroflumethiazide more profitable than hydrochlorothiazide?
No. Hydrochlorothiazide generally has broader demand and stronger supplier coverage. Bendroflumethiazide may achieve temporary value in a supply-constrained niche, but it lacks the scale and market breadth of hydrochlorothiazide.
Are bendroflumethiazide combination products patent protected?
Historic combination patents are generally expected to have expired. A new combination could receive patent protection only if it meets applicable novelty and inventive-step standards, and any protection would attach to the new product rather than the old active ingredient alone.
What is the main commercial risk for bendroflumethiazide?
The main risk is loss of supply caused by low profitability, supplier withdrawal, or active pharmaceutical ingredient constraints. Therapeutic substitution is the primary long-term demand risk.
References
- Electronic Medicines Compendium. (n.d.). Bendroflumethiazide tablets: Summary of product characteristics. Datapharm Ltd.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book.
- U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs.
- National Institute for Health and Care Excellence. (2019). Hypertension in adults: Diagnosis and management (NG136). NICE.
- National Institute for Health and Care Excellence. (2013). Chronic heart failure in adults: Diagnosis and management (NG106). NICE.
More… ↓
